O gemfibrozil reduz níveis elevados de lipoproteína (a) em pacientes hipercolesterolêmicos / Gemfibrozil reduces elevated lipoprotein (a) levels in hypercholesterolemic patients
Arq. bras. cardiol
; 68(4): 257-260, Abr. 1997.
Article
in Pt
| LILACS
| ID: lil-320341
Responsible library:
BR1.1
ABSTRACT
PURPOSE:
To compare the effects of gemfibrozil and lovastatin in patients with hypercholesterolemia and increased lipoprotein(a) [Lp(a)] levels.METHODS:
Twenty-seven subjects with total cholesterol (TC) > 240 mg/dL, LDL-C > 160 mg/dL and Lp(a) > 25 mg/dL were studied. Patients were randomized to receive gemfibrozil 1200 mg/day, (n = 14, 54 +/- 7 years) or lovastatin 40-80 mg at night (n = 13, 55 +/- 9 years) for 12 weeks. Lipid profile and Lp(a) were determined at 4 and 12 weeks of treatment.RESULTS:
Gemfibrozil reduced TC (-21), LDL-C (-26), triglycerides (TG)(-48) and Lp(a) (-25), increased HDL-C (+48)(p < 0.001). Lovastatin reduced TC (-29), LDL-C (-37) and TG (-25) (p < 0.001) however, it did not affect Lp(a).CONCLUSION:
Besides reducing plasma LDL-C, TG and increasing HDL-C, gemfibrozil effectively lowers Lp(a) levels. Lovastatin did not affect Lp(a) levels.
Full text:
1
Collection:
01-internacional
Database:
LILACS
Main subject:
Lovastatin
/
Gemfibrozil
/
Lipoprotein(a)
/
Hypercholesterolemia
/
Anticholesteremic Agents
/
Hypolipidemic Agents
Type of study:
Clinical_trials
Limits:
Female
/
Humans
/
Male
Language:
Pt
Journal:
Arq. bras. cardiol
Journal subject:
CARDIOLOGIA
Year:
1997
Document type:
Article
Affiliation country:
Brazil
Country of publication:
Brazil